The Biopharmaceuticals Field And Algae As Expression Hosts
Published 2016 · Biology
Download PDFAnalyze on Scholarcy
Biopharmaceuticals (BFs) are molecules of biological origin and complex composition including vaccines, antibodies, hormones, clotting factors, growth factors, and cytokines that are used in addressing a variety of conditions. Despite of decades having recombinant DNA technology and sustained pharmaceutical industry development, the world faces a serious need for accessible biopharmaceuticals. Access to vaccines and other therapeutics is limited in developing countries where public resources are not sufficient to make them accessible to cope with the costs associated to their production, distribution through cold chain, and safe parenteral administration. The production of biosimilars and biobetters is opening an opportunity to improve efficacy and save resources in this field. In parallel, biotechnological alternatives for BFs production are gaining interest. In particular, genetically engineered photosynthetic organisms have been explored as biofactories and even delivery vehicles. In particular, algae species have been proposed as a low cost and convenient platform for the production of BFs. This chapter serves as an introduction to this book by presenting a brief overview of the BFs field as well as the general features of algae species that make them attractive as BFs biofactories.
This paper references
Overview of bacterial expression systems for heterologous protein production: from molecular and biochemical fundamentals to commercial systems
K. Terpe (2006)
In Metabolic Engineering of Eukaryotic Microalgae: Potential and Challenges Come with Great Diversity
Javier A. Gimpel (2015)
Saving money in the European healthcare systems with biosimilars
Robert Haustein (2012)
Stable expression of hepatitis B surface antigen gene in Dunaliella salina (Chlorophyta)
Degui Geng (2004)
Food-Grade Organisms as Vaccine Biofactories and Oral Delivery Vehicles.
S. Rosales-Mendoza (2016)
Development of a stepwise aeration control strategy for efficient docosahexaenoic acid production by Schizochytrium sp.
Lu-jing Ren (2010)
Chlamydomonas and Arabidopsis. A Dynamic Duo1
Benjamin L. Gutman (2004)
Microalgal drying and cell disruption--recent advances.
K. Show (2015)
Large-scale production of pharmaceutical proteins in plant cell culture-the Protalix experience.
Yoram Tekoah (2015)
When biotech proteins go off-patent.
H. Schellekens (2004)
Chlamydomonas reinhardtii as the photosynthetic yeast.
J. Rochaix (1995)
Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe.
F. Rencz (2015)
Plant‐produced candidate countermeasures against emerging and reemerging infections and bioterror agents
S. Streatfield (2015)
Vaccination against Influenza with Recombinant Hemagglutinin Expressed by Schizochytrium sp. Confers Protective Immunity
Anne-Cécile V. Bayne (2013)
Better and faster: improvements and optimization for mammalian recombinant protein production.
S. Almo (2014)
Do Red and Green Make Brown?: Perspectives on Plastid Acquisitions within Chromalveolates
R. Dorrell (2011)
Recombinant protein subunit vaccine synthesis in microbes: a role for yeast?
R. M. Bill (2015)
The Corn Smut (‘Huitlacoche’) as a New Platform for Oral Vaccines
Margarita Juárez-Montiel (2015)
Ice recrystallization inhibition mediated by a nuclear-expressed and -secreted recombinant ice-binding protein in the microalga Chlamydomonas reinhardtii
K. Lauersen (2013)
COMMERCIAL DEVELOPMENTS IN MICROALGAL BIOTECHNOLOGY
K. Apt (1999)
Oddities and Curiosities in the Algal World
L. Barsanti (2008)
Establishing Chlamydomonas reinhardtii as an industrial biotechnology host
Mark A. Scaife (2015)
Production of Natural Biopharmaceuticals from the Microalgae Living in the Dead Sea
Sadeq Emeish (2013)
Improvement of efficiency of genetic transformation for Dunaliella salina by glass beads method
Shuying Feng (2008)
Molecular phylogeny and taxonomic revision of Chlamydomonas (Chlorophyta). I. Emendation of Chlamydomonas Ehrenberg and Chloromonas Gobi, and description of Oogamochlamys gen. nov. and Lobochlamys gen. nov.
T. Pröschold (2001)
Microalgal feeds for aquaculture
R. Gladue (2004)
What's fueling the biotech engine--2010 to 2011.
S. Aggarwal (2011)
Commercial development of microalgal biotechnology: from the test tube to the marketplace.
M. Olaizola (2003)
Biosimilars: A consideration of the regulations in the United States and European union.
J. Daller (2016)
The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries
A. Finckh (2015)
Algal productivity modeling: A step toward accurate assessments of full‐scale algal cultivation
Q. Béchet (2015)
First biosimilar drug approved in the USA.
Talha Khan Burki (2015)
An engineered diatom acting like a plasma cell secreting human IgG antibodies with high efficiency
F. Hempel (2012)
Investigating the dynamics of recombinant protein secretion from a microalgal host.
K. Lauersen (2015)
The art of CHO cell engineering: A comprehensive retrospect and future perspectives.
Simon Fischer (2015)
Über die Geschwindigkeit der photochemischen Kohlensäurezersetzung in lebenden Zellen. II
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
W. Strohl (2015)
Preparation of transgenic Dunaliella salina for immunization against white spot syndrome virus in crayfish
Shuying Feng (2013)
How similar do 'biosimilars' need to be?
H. Schellekens (2004)
The Cost Savings Potential of Biosimilar Drugs in the United States
A. Mulcahy (2014)
Extremophilic micro-algae and their potential contribution in biotechnology.
P. Varshney (2015)
What's fueling the biotech engine—2008
S. Aggarwal (2009)
Cultivo de cepas de Dunaliella salina (Teodoresco 1905) en diferentes medios bajo condiciones de laboratorio
Oscar Parra (1996)
Chlamydomonas reinhardtii as a viable platform for the production of recombinant proteins: current status and perspectives
S. Rosales-Mendoza (2011)
Stable nuclear transformation of the diatomPhaeodactylum tricornutum
K. Apt (2005)
Recent advances in microalgal bioscience in Japan, with special reference to utilization of biomass and metabolites: a review
K. Yamaguchi (2004)
Dose-response of supplementing marine algae (Schizochytrium spp.) on production performance, fatty acid profiles, and wool parameters of growing lambs.
Sarah J Meale (2014)
Manipulating the glycosylation pathway in bacterial and lower eukaryotes for production of therapeutic proteins.
Diana Chinyere Anyaogu (2015)
Algae as Protein Factories: Expression of a Human Antibody and the Respective Antigen in the Diatom Phaeodactylum tricornutum
F. Hempel (2011)
Cultivation, photobioreactor design and harvesting of microalgae for biodiesel production: a critical review.
C. Chen (2011)
Plant-based oral delivery of β-glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease.
Yoseph Shaaltiel (2015)
Diatoms: Biology and Morphology of the Genera
F. E. Round (1990)
Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics.
S. A. Kellermann (2002)
Heterotrophic production of long chain omega-3 fatty acids utilizing algae and algae-like microorganisms
W. Barclay (2004)
Biotechnological exploitation of microalgae.
Doris Gangl (2015)
The Chlamydomonas genome reveals its secrets: chaperone genes and the potential roles of their gene products in the chloroplast
M. Schroda (2004)
Plant organelles contain distinct peptidylprolyl cis,trans-isomerases.
A. Breiman (1992)
Protein disulfide isomerase as a regulator of chloroplast translational activation.
J. Kim (1997)
Moss‐made pharmaceuticals: from bench to bedside
R. Reski (2015)
Taxonomic rearrangement of the genus Schizochytrium sensu lato based on morphology, chemotaxonomic characteristics, and 18S rRNA gene phylogeny (Thraustochytriaceae, Labyrinthulomycetes): emendation for Schizochytrium and erection of Aurantiochytrium and Oblongichytrium gen. nov.
Rinka Yokoyama (2007)
The biotechnology of cultivating the halotolerant algaDunaliella
A. Ben-Amotz (1990)
Biosimilar, biobetter and next generation therapeutic antibodies
A. Beck (2011)
Solubilization and refolding of bacterial inclusion body proteins.
S. Singh (2005)
Realizing the promises of marine biotechnology.
Esther E. M. Luiten (2003)
Chloroplast transformation in Chlamydomonas with high velocity microprojectiles.
J. Boynton (1988)
Therapeutic antibodies: market considerations, disease targets and bioprocessing.
J. Elvin (2013)
Evolution of the Global Burden of Viral Infections from Unsafe Medical Injections, 2000–2010
J. Pépin (2014)
Production of recombinant proteins by yeast cells.
E. Çelik (2012)
Production of recombinant proteins in microalgae at pilot greenhouse scale
Javier A. Gimpel (2015)
Characterization of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori)
Minoru Tada (2015)
Public Acceptance of Plant Biotechnology and GM Crops
J. M. Lucht (2015)
Robust Expression and Secretion of Xylanase1 in Chlamydomonas reinhardtii by Fusion to a Selection Gene and Processing with the FMDV 2A Peptide
B. Rasala (2012)
THE CHEMICAL COMPOSITION OF CHLORELLA; EFFECT OF ENVIRONMENTAL CONDITIONS.
H. A. Spoehr (1949)
Core Concepts: Biosimilars
S. Ornes (2015)
Recombinant protein production in bacterial hosts.
T. Overton (2014)